Key Points
- CFO Christian Klemt sold 12,000 shares on March 4 at an average price of $9.06 for a total of $108,720, trimming his stake by about 5.03% to 226,581 shares.
- A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful, raising the probability of additional randomized, placebo‑controlled trials and significant regulatory delays.
- The FDA rebuke and broad media scrutiny have driven sharp stock volatility (roughly a 32% one‑week plunge and an intraday 34% jump to $14.27), led to analyst downgrades, and prompted multiple class‑action/shareholder lawsuit notices, with other insiders also selling shares.
uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Jeannette Potts sold 3,412 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the sale, the insider directly owned 138,483 shares in the company, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
uniQure Stock Up 34.0%
Shares of uniQure stock traded up $3.62 during trading hours on Friday, hitting $14.27. The company had a trading volume of 16,602,429 shares, compared to its average volume of 4,315,633. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12. The company's 50-day moving average is $22.04 and its two-hundred day moving average is $29.43. The company has a market cap of $892.30 million, a P/E ratio of -4.14 and a beta of 0.73. uniQure N.V. has a twelve month low of $7.76 and a twelve month high of $71.50.
uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.
Institutional Trading of uniQure
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC lifted its position in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company's stock worth $147,170,000 after acquiring an additional 1,705,556 shares during the period. Aberdeen Group plc lifted its holdings in shares of uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company's stock worth $88,030,000 after purchasing an additional 738,897 shares during the period. State Street Corp grew its position in uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company's stock valued at $77,319,000 after buying an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. increased its stake in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company's stock valued at $70,226,000 after buying an additional 1,785,275 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new position in uniQure during the 2nd quarter worth $29,217,000. 78.83% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on QURE. TD Cowen reissued a "buy" rating on shares of uniQure in a report on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of uniQure in a research report on Wednesday, January 21st. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research note on Tuesday, February 10th. The Goldman Sachs Group decreased their price objective on uniQure from $37.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $34.33.
Check Out Our Latest Stock Report on uniQure
More uniQure News
Here are the key news stories impacting uniQure this week:
- Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
- Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
- Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
- Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
- Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
- Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
- Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.
About uniQure
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
